Pancreatic Cancer: Epidemiology Forecast to 2026 - Product Image

Pancreatic Cancer: Epidemiology Forecast to 2026

  • ID: 4544528
  • Report
  • 42 pages
  • GlobalData
1 of 3
Pancreatic Cancer: Epidemiology Forecast to 2026

Summary

Pancreatic cancer is one of the most fatal cancers around the world, with the highest incidence and mortality rates found in developed countries (Michaud, 2004). Pancreatic cancer occurs when cells in the pancreas develop mutations in their DNA, and grow uncontrollably. These accumulating cells form a tumor. Untreated pancreatic cancer spreads to nearby organs and blood vessels. Pancreatic adenocarcinoma or pancreatic exocrine cancer is the most common type of pancreatic cancer, and begins in the cells that line the ducts of the pancreas. Rarely, cancer can form in the hormone-producing cells or the neuroendocrine cells of the pancreas. These types of cancer are called islet cell tumors, pancreatic endocrine cancer, or pancreatic neuroendocrine tumors (PNETs).

In 2016, the 7MM had 149,780 diagnosed incident cases of pancreatic cancer. This is expected to increase to 182,557 diagnosed incident cases by 2026, at an Annual Growth Rate (AGR) of 2.19%. The increase is driven by the aging population in the 7MM. In 2016, the 7MM had 106,133 five-year diagnosed prevalent cases of pancreatic cancer. This is expected to increase to 131,769 diagnosed prevalent cases by 2026, at an AGR of 2.42%. The US had the highest number of diagnosed incident and five-year diagnosed prevalent cases of pancreatic cancer. The development of more effective therapies, particularly for elderly patients, would improve survival and increase disease prevalence.

The report "Pancreatic Cancer: Epidemiology Forecast to 2026", provides an overview of the risk factors and global trends of pancreatic cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the following segmentations in ages 15 years and older across the 7MM: diagnosed incident cases of pancreatic cancer (excluding PNETs); five-year diagnosed prevalent cases of pancreatic cancer (excluding PNETs); diagnosed incident cases of pancreatic cancer (excluding PNETs) by cancer stages at diagnosis; diagnosed incident cases of familial pancreatic cancer (excluding PNETs); diagnosed incident cases of familial pancreatic cancer (excluding PNETs) by germline mutations; and diagnosed incident cases of pancreatic cancer (excluding PNETs) by KRAS mutations.

Scope
  • The pancreatic cancer Epidemiology Forecast report provides an overview of the risk factors and global trends of pancreatic cancer in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • This report also includes a 10-year epidemiological forecast for the following segmentations in ages 15 years and older across the 7MM: diagnosed incident cases of pancreatic cancer (excluding PNETs); five-year diagnosed prevalent cases of pancreatic cancer (excluding PNETs); diagnosed incident cases of pancreatic cancer (excluding PNETs) by cancer stages at diagnosis; diagnosed incident cases of familial pancreatic cancer (excluding PNETs); diagnosed incident cases of familial pancreatic cancer (excluding PNETs) by germline mutations; and diagnosed incident cases of pancreatic cancer (excluding PNETs) by KRAS mutations.
  • The pancreatic cancer epidemiology forecast report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Forecast Report is in-depth, high quality, transparent, and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to buy

The Pancreatic Cancer Epidemiology Forecast report will allow you to:
  • Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer market.
  • Quantify patient populations in the global pancreatic cancer market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for pancreatic cancer therapeutics in each of the markets covered.
  • Understand magnitude of pancreatic cancer population by mutations.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents

2 Pancreatic Cancer: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.3.1 Incidence
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Incident Cases of Pancreatic Cancer (Excluding PNETs)
3.4.4 Diagnosed Incident Cases of Pancreatic Cancer (Excluding PNETs) by Cancer Stages at Diagnosis
3.4.5 Diagnosed Incident Cases of Familial Pancreatic Cancer
3.4.6 Diagnosed Incident Cases of Familial Pancreatic Cancer by Germline Mutations
3.4.7 Diagnosed Incident Cases of Pancreatic Cancer (Excluding PNETs) by Other Mutations
3.4.8 Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer (Excluding PNETs)
3.5 Epidemiological Forecast for Pancreatic Cancer (2016-2026)
3.5.1 Diagnosed Incident Cases of Pancreatic Cancer
3.5.2 Age-Specific Diagnosed Incident Cases of Pancreatic Cancer
3.5.3 Sex-Specific Diagnosed Incident Cases of Pancreatic Cancer
3.5.4 Diagnosed Incident Cases of Pancreatic Cancer by Cancer Stages at Diagnosis
3.5.5 Diagnosed Incident Cases of Familial Pancreatic Cancer
3.5.6 Diagnosed Incident Cases of Familial Pancreatic Cancer by Germline Mutations
3.5.7 Diagnosed Incident Cases of Pancreatic Cancer by Other Mutations
3.5.8 Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of Analysis
3.6.3 Strengths of Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About
4.4 Contact
4.5 Disclaimer

List of Tables
Table 1: Risk Factors for Pancreatic Cancer
Table 2: 7MM, Diagnosed Incident Cases of Familial Pancreatic Cancer, Ages =15 Years, N, Both Sexes, Select Years 2016-2026

List of Figures
Figure 1: 7MM, Diagnosed Incident Cases of Pancreatic Cancer (N), Both Sexes, Ages =15 Years, 2016 and 2026
Figure 2: 7MM, Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer (N), Both Sexes, Ages =15 Years, 2016 and 2026
Figure 3: 7MM, Age-Standardized Diagnosed Incidence of Pancreatic Cancer (Cases per 100,000 Population), Men, Ages =15 Years, 2006 to 2026
Figure 4: 7MM, Age-Standardized Diagnosed Incidence of Pancreatic Cancer (Cases per 100,000 Population), Women, Ages =15 Years, 2006 to 2026
Figure 5: 7MM, Sources Used for Diagnosed Incident Cases of Pancreatic Cancer
Figure 6: 7MM, Sources Used for Relative Survival Proportions to Forecast the Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer
Figure 7: 7MM, Sources Used for Diagnosed Incident Cases of Pancreatic Cancer by Cancer Stages at Diagnosis
Figure 8: 7MM, Sources Used for Diagnosed Incident Cases of Familial Pancreatic Cancer
Figure 9: 7MM, Sources Used for Diagnosed Incident Cases of Familial Pancreatic Cancer by Germline Mutations
Figure 10: 7MM, Sources Used for Diagnosed Incident Cases of Familial Pancreatic Cancer by Other Mutations
Figure 11: 7MM, Diagnosed Incident Cases of Pancreatic Cancer, Both Sexes, Ages =15 Years, N, 2016
Figure 12: 7MM, Age-Specific Diagnosed Incident Cases of Pancreatic Cancer, Both Sexes, Ages =15 Years, N, 2016
Figure 13: 7MM, Sex-Specific Diagnosed Incident Cases of Pancreatic Cancer, Ages =15 Years, N, 2016
Figure 14: 7MM, Diagnosed Incident Cases of Pancreatic Cancer by Cancer Stages at Diagnosis, Both Sexes, Ages =15 Years, N, 2016
Figure 15: 7MM, Diagnosed Incident Cases of Familial Pancreatic Cancer by Germline Mutations, Both Sexes, Ages =15 Years, N, 2016 to 2026
Figure 16: 7MM, Diagnosed Incident Cases of Pancreatic Cancer by Other Mutations, Both Sexes, Ages =15 Years, N, 2016 to 2026
Figure 17: 7MM, Five-Year Diagnosed Prevalent Cases of Pancreatic Cancer, Both Sexes, Ages =15 Years, N, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll